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access to FP treatment and ensuring all patients of child-
bearing potential receive education at time of cancer diagnosis.
234
Raising the Bar of Oncofertility Care in HSCT Patients:
Implementation of an Oncofertility Education and
Referral Program
Hannah E. Spencer 1, Geoffrey Barkley 2, Laura P. Smith 3,
Gana Elizabeth Locker 4, Diana O. Rexrode 5, Amer Beitinjaneh 1,
Leonid Volodin 1, Lisa Huntsinger 6, Tamila L. Kindwall-Keller 1.
1 Hematology Oncology, University of Virginia School of
Medicine, Charlottesville, VA; 2 Stem Cell Transplant, University
of Virginia, Charlottesville, VA; 3 Reproductive Medicine and
Surgery Center of Virignia, Charlottesville, VA; 4 Stem Cell
Transplant, University of Virginia Health System,
Charlottesville, VA; 5 Stem Cell Transplant Program, University
of Virginia, Charlottesville, VA; 6 University of Virginia Health
System, Charlottesville, VA
Background: Hematopoietic stem cell transplant (HSCT) sur-
vivors and their partners frequently struggle with infertility
post HSCT, which can decrease quality of life (QOL). With an
increasing number of HSCT survivors, a systematic pre-trans-
plant and survivorship care plan that includes oncofertility is
eagerly needed. A comprehensive guideline on oncofertility
education and referral does not exist for HSCT patients.
Therefore, our HSCT program developed an Oncofertility Ed-
ucation and Referral Program (OERP) to empower HSCT phy-
sicians, nurses, and patients with knowledge of fertility
preservation (FP) and family planning options. The strategy
and tools of our OERP implementation can assist transplant
groups at other institutions in initiating similar programs.
Methods: A multidisciplinary team identiﬁed barriers that
providersexperience indeliveringoncofertilityeducation, and
dealing with programmatic barriers for referrals to repro-
ductive specialists. The American Society of Clinical Oncology
(ASCO) and National Comprehensive Cancer Network (NCCN)
guidelines on oncofertility education were used to develop
program-speciﬁc guidelines and educational material for
providers and patients. A referral network was built through
collaboration with local reproductive medicine specialists.
Results: OERP implementation occurred over a 12-month
period fromJuly2013 to July2014 (Figure1).Weput into service
a standard operating procedure (SOP) on FP Education and
Referral that incorporated ASCO and NCCN guidelines as
well as a referral algorithmwith contact information. Biannual
in-service oncofertility education sessions were provided to
HSCT physicians, nurses, and support staff. Provider educationFigure 1. Flow chart depicting strategy andpackets that include national guidelines, referral contacts,
and support services were made available on the shared drive
for anytime access. Patient education packets that contain a
one-page fact sheet, local reproductive medicine clinic
information, FP ﬁnancial assistance, and support services
were also made available on shared drive. Oncofertility
discussions were incorporated into programmatic patient care
committee meetings and patient intake education sessions to
ensure oncofertility education is delivered from the beginning
of patient care. A computer-based learning module was
created for continuing education and is undergoing
institutional review for implementation.
Conclusions: We created a comprehensive OERP for HSCT
providers and patients. Success of the OERPwill bemeasured
annually through reproductive specialist referral metrics and
surveys given periodically to patients and providers. In an
effort to improve HSCT survivors’ QOL, programs should
implement an OERP to ensure patients make informed de-
cisions concerning the future of their reproductive health
before undergoing HSCT.235
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Introduction: Long-term stable mixed chimerism (MC) is
rare after allogeneic hematopoietic stem cell transplantation
(HSCT). MC is deﬁned as 5-95% residual recipient hemato-
poietic cells beyond one-year post-HSCT. The mechanisms
directing hematopoietic recovery to MC in some patients and
to full donor chimerism (DC) in others are poorly understood.
Methods: We compared patients with DC and long-term
stable MC for a median of 9.5 years post-HSCT. Both the
clinical situation and the immune system (functional and
phenotypic properties) were investigated by questionnaires,
western blot, multiplex bead-based immunoassay, ELISA and
ﬂow cytometry. Blood samples were drawn at 2 weeks and
>5 years post-HSCT. Additionally, lineage-speciﬁc chimerism
status in the MC patients was determined. The results were
analyzed by the Mann-Whitney U test, Fisher’s exact test and
Spearman’s rank correlation coefﬁcient.processes of OERP implementation.
